Establishment of novel immunotherapy against nasal NK/T cell lymphoma

2023 Fiscal Year Final Research Report

• Project/Area Number: 21H03082
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Asahikawa Medical College
• Principal Investigator: Harabuchi Yasuaki 旭川医科大学, 医学部, 名誉教授 (80208686)
• Co-Investigator(Kenkyū-buntansha): 熊井 琢美 旭川医科大学, 医学部, 講師 (00596306) ; 大原 賢三 旭川医科大学, 医学部, 講師 (20596308) ; 高原 幹 旭川医科大学, 医学部, 講師 (50322904) ; 大栗 敬幸 旭川医科大学, 医学部, 准教授 (70564061) ; 長門 利純 旭川医科大学, 医学部, 講師 (80431419) ; 岸部 幹 旭川医科大学, 医学部, 講師 (80447101) ; 小林 博也 旭川医科大学, 医学部, 教授 (90280867)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: NK/T細胞リンパ腫

Outline of Final Research Achievements

In this series of research, we have examined the multiple oncogenic factors of nasal NK/T cell lymphoma. We have focued on Epstein-Barr virus-derived LMP1. This protein has a multiple role to support this type of lymphoma by inducing factors that are related to lymphoma progression. In addition, we found that chemokine and its receptor play a significant role in tumor proliferation. Especially, CCR4 could be a promising target as an antibody-dependent cellular toxicity-based lymphoma suppression. In addition, we have found that this lymphoma would be a target of antitumor immune cells such as cytotoxic helper T cells. c-Met was expressed in this lymphoma that could be killed by c-Met-reactive CD4 T cells. CD27/CD70 and PD-1/PD-L1 signalings also play role in this lymphoma to escape from antitumor immune cells.

Free Research Field

頭頸部癌

Academic Significance and Societal Importance of the Research Achievements

免疫抑制の解除と腫瘍特異的免疫の活性化を同時に標的とした治療法は他の悪性腫瘍においても報告がないため本研究の独自性および創造性は担保されており、臨床応用を目指した実用的な研究と考えられる。さらに、本研究で創出した新規治療アプローチは、腫瘍の組織型によってエピトープペプチドを変更することでその他の悪性腫瘍にも応用可能な治療戦略となることが期待される。